Overview

Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The study will be a non-randomized, open label, single dose, single blind, placebo control, single center, single arm study in Type I diabetes patients. The study will include single dose administration for the evaluation of single dose acute toxicity, pharmacokinetics and activity.
Phase:
Phase 1
Details
Lead Sponsor:
Oshadi Drug Administration
Treatments:
Insulin
Insulin, Globin Zinc